MIAMI, FL (September 30, 2024) – Lavior Pharma Inc., an International advanced diabetic wound and skincare Company headquartered in Miami, Florida, announced the appointment of J. David Warren, Ph.D, to the Company’s Scientific Executive Advisory Board.
Dr. J. David Warren is an Adjunct Associate Professor of Research in Biochemistry at Weill Cornell Medicine and Senior Principal Scientist at Canary Oncoceutics. Dr. Warren is an experienced researcher in the field of bioorganic and medicinal chemistry who has placed several compounds into advanced preclinical development. His accomplishments include the development of methodology that allows for the total chemical synthesis of fully glycosylated proteins; the synthesis and application of new photostable fluorophores; the development of novel therapeutics for the treatment of Niemann-Pick type C (NPC) disease; the discovery of nucleoside analogs active against adenosine kinase; the discovery of selective inhibitors of HCN1 for the treatment of neuropathic pain; the discovery of novel PET tracers for imaging the chemokine receptor CXCR4; the identification of a small molecule inhibitor of 3-phosphoglycerate dehydrogenase to target serine biosynthesis in cancer; the discovery and development of inhibitors selective for mycobacterial versus human proteasomes; and the CURE-PRO platform, an innovative new approach to targeted protein degradation. Dr. Warren received his PhD degree from Colorado State University, where he was awarded a graduate fellowship from Boehringer Ingelheim and carried out postdoctoral studies at the Memorial Sloan-Kettering Cancer Center as an NIH-supported fellow. He holds 10 issued US and international patents and has published over 50 peer-reviewed publications and book chapters.
“We are delighted to announce that Dr. J David Warren has joined our scientific advisory board. His profound knowledge of biochemistry will be instrumental in guiding our research and driving the development of groundbreaking solutions.” says Gilad Savion, the CEO and President of Lavior.
About Lavior Pharma Inc.
LAVIOR is the only company exclusively dedicated to the therapeutic diabetes skin care market. The LAVIOR skincare product line soothes and heals some of the most widespread and challenging skin problems – diabetic ulcers, wounds, burns, eczema/atopic dermatitis, bacterial and fungal infections, skin irritations, and cracked skin. LAVIOR’s line of products is based on the proven efficacy of the Inula AGS RIED botanical species. They are developed using the highest quality, pharmaceutical grade ingredients; manufactured and tested to deliver safe, effective, and compliant products. Backed by over 13 years of extensive research and clinical trials, proven clinical safety and efficacy, they consistently outperform conventional treatments.
For more information on Lavior Pharma and its products, please visit www.lavior.com
For Media or other Inquiries, please contact:
Anabelle Savion
Managing Director
Phone: (+1) 9178373355
anabelle@lavior.com
